Progeria: a human-disease model of accelerated aging

1992 ◽  
Vol 55 (6) ◽  
pp. 1222S-1224S ◽  
Author(s):  
W T Brown
2012 ◽  
Vol 21 (4) ◽  
pp. 699-713 ◽  
Author(s):  
V. Duranthon ◽  
N. Beaujean ◽  
M. Brunner ◽  
K. E. Odening ◽  
A. Navarrete Santos ◽  
...  

2016 ◽  
Vol 10 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Hiroko Tabunoki ◽  
Hidemasa Bono ◽  
Katsuhiko Ito ◽  
Takeshi Yokoyama

2020 ◽  
Author(s):  
Min Zhang ◽  
Peng Wang ◽  
Ronghua Luo ◽  
Yaqing Wang ◽  
Zhongyu Li ◽  
...  

AbstractCoronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that seriously endangers human health. There is an urgent need to build physiological relevant human models for deep understanding the complex organ-level disease processes and facilitating effective therapeutics for COVID-19. Here, we first report the use of microengineered alveolus chip to create a human disease model of lung injury and immune responses induced by native SARS-CoV-2 at organ-level. This biomimetic system is able to reconstitute the key features of human alveolar-capillary barrier by co-culture of alveolar epithelial and microvascular endothelial cells under microfluidic flow. The epithelial cells on chip showed higher susceptibility to SARS-CoV-2 infection than endothelial cells identified by viral spike protein expression. Transcriptional analysis showed distinct responses of two cell types to SARS-CoV-2 infection, including activated type I interferon (IFN-I) signaling pathway in epithelium and activated JAK-STAT signaling pathway in endothelium. Notably, in the presence of circulating immune cells, a series of alveolar pathological changes were observed, including the detachment of endothelial cells, recruitment of immune cells, and increased production of inflammatory cytokines (IL-6, IL-8, IL-1β and TNF-α). These new findings revealed a crucial role of immune cells in mediating lung injury and exacerbated inflammation. Treatment with antiviral compound remdesivir could suppress viral copy and alleviate the disruption of alveolar barrier integrity induced by viral infection. This bioengineered human organ chip system can closely mirror human-relevant lung pathogenesis and immune responses to SARS-CoV-2 infection, not possible by other in vitro models, which provides a promising and alternative platform for COVID-19 research and preclinical trials.


2012 ◽  
Vol 4 (159) ◽  
pp. 159ra147-159ra147 ◽  
Author(s):  
Dongeun Huh ◽  
Daniel C. Leslie ◽  
Benjamin D. Matthews ◽  
Jacob P. Fraser ◽  
Samuel Jurek ◽  
...  

2020 ◽  
pp. 2002928
Author(s):  
Min Zhang ◽  
Peng Wang ◽  
Ronghua Luo ◽  
Yaqing Wang ◽  
Zhongyu Li ◽  
...  

2015 ◽  
Vol 2016 (1) ◽  
pp. 4-22 ◽  
Author(s):  
M. I. Stamou ◽  
K. H. Cox ◽  
William F. Crowley

Abstract The neuroendocrine regulation of reproduction is an intricate process requiring the exquisite coordination of an assortment of cellular networks, all converging on the GnRH neurons. These neurons have a complex life history, migrating mainly from the olfactory placode into the hypothalamus, where GnRH is secreted and acts as the master regulator of the hypothalamic-pituitary-gonadal axis. Much of what we know about the biology of the GnRH neurons has been aided by discoveries made using the human disease model of isolated GnRH deficiency (IGD), a family of rare Mendelian disorders that share a common failure of secretion and/or action of GnRH causing hypogonadotropic hypogonadism. Over the last 30 years, research groups around the world have been investigating the genetic basis of IGD using different strategies based on complex cases that harbor structural abnormalities or single pleiotropic genes, endogamous pedigrees, candidate gene approaches as well as pathway gene analyses. Although such traditional approaches, based on well-validated tools, have been critical to establish the field, new strategies, such as next-generation sequencing, are now providing speed and robustness, but also revealing a surprising number of variants in known IGD genes in both patients and healthy controls. Thus, before the field moves forward with new genetic tools and continues discovery efforts, we must reassess what we know about IGD genetics and prepare to hold our work to a different standard. The purpose of this review is to: 1) look back at the strategies used to discover the “known” genes implicated in the rare forms of IGD; 2) examine the strengths and weaknesses of the methodologies used to validate genetic variation; 3)substantiate the role of known genes in the pathophysiology of the disease; and 4) project forward as we embark upon a widening use of these new and powerful technologies for gene discovery. (Endocrine Reviews 36: 603–621, 2015)


Sign in / Sign up

Export Citation Format

Share Document